Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC2 | P15153 | 1/20 | 0.32 |
| ▸ | RAC3 | P60763 | 1/20 | 0.32 |
| ▸ | CDC42 | P60953 | 1/20 | 0.32 |
| ▸ | RAC1 | P63000 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532369 | 0.96 | SLC5A1 (0.33) | SLC5A1SLC5A2KDM4EATML3MBTL1 | |
| SCHEMBL21532762 | 0.96 | RAC2 (0.32) | RAC2RAC3CDC42RAC1SLC5A1 | |
| SCHEMBL21532215 | 0.93 | SMN1; SMN2 (0.32) | KDM4EATML3MBTL1KMT2AMEN1 | |
| SCHEMBL21532216 | 0.93 | PTGER4 (0.34) | KDM4EATML3MBTL1 | |
| SCHEMBL21532760 | 0.93 | SLC5A1 (0.33) | SLC5A1SLC5A2KDM4EATML3MBTL1 | |
| SCHEMBL21532595 | 0.91 | RAC2 (0.33) | RAC2RAC3CDC42RAC1SLC5A1 | |
| SCHEMBL21532230 | 0.89 | PTGER4 (0.34) | KDM4EATML3MBTL1 | |
| SCHEMBL21532223 | 0.89 | SMN1; SMN2 (0.32) | KDM4EATML3MBTL1KMT2AMEN1 | |
| SCHEMBL17636666 | 0.88 | KDM4E (0.41) | RAC2RAC3CDC42RAC1KDM4E | |
| SCHEMBL21532748 | 0.88 | KMT2A (0.32) | RAC2RAC3CDC42RAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | CRY1, CCNT1, CCNA1 | RAC2 2614/4885RAC3 3379/4885CDC42 3197/4885 |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, ARL1 | RAC2 2879/4885RAC3 3793/4885CDC42 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.